TY - JOUR
T1 - How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
AU - El Chaer, Firas
AU - Auletta, Jeffery J.
AU - Chemaly, Roy F.
N1 - Funding Information:
The authors thank Ann Sutton in Editing Services in the Research Medical Library at The University of Texas MD Anderson Cancer Center for editing the manuscript and David Aten in the Medical Illustration Department at The University of Texas MD Anderson Cancer Center for creating the images.
Funding Information:
Conflict-of-interest disclosure: R.F.C. has received research funding from Karius, Merck, AiCuris, Viracor-Eurofins, Takeda, Genentech, and Ansun Pharmaceuticals and is a consultant for ADMA Biologics, Janssen, Merck, Molecular Therapeutics, Takeda, Oxford Immunotec, Karius, Shinogi, and Ansun Pharmaceuticals. The remaining authors declare no competing financial interests.
Publisher Copyright:
© 2022 American Society of Hematology
PY - 2022/8/18
Y1 - 2022/8/18
N2 - Patients with hematologic malignancies and recipients of hematopoietic cell transplantation (HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have a higher risk of morbidity and mortality after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Compared with the general population, these patients have suboptimal humoral responses to COVID-19 vaccines and subsequently increased risk for breakthrough infections, underscoring the need for additional therapies, including pre- and postexposure prophylaxis, to attenuate clinical progression to severe COVID-19. Therapies for COVID-19 are mostly available for adults and in the inpatient and outpatient settings. Selection and administration of the best treatment options are based on host factors; virus factors, including circulating SARS-CoV-2 variants; and therapeutic considerations, including the clinical efficacy, availability, and practicality of treatment and its associated side effects, including drug-drug interactions. In this paper, we discuss how we approach managing COVID-19 in patients with hematologic malignancies and recipients of HCT and cell therapy.
AB - Patients with hematologic malignancies and recipients of hematopoietic cell transplantation (HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have a higher risk of morbidity and mortality after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Compared with the general population, these patients have suboptimal humoral responses to COVID-19 vaccines and subsequently increased risk for breakthrough infections, underscoring the need for additional therapies, including pre- and postexposure prophylaxis, to attenuate clinical progression to severe COVID-19. Therapies for COVID-19 are mostly available for adults and in the inpatient and outpatient settings. Selection and administration of the best treatment options are based on host factors; virus factors, including circulating SARS-CoV-2 variants; and therapeutic considerations, including the clinical efficacy, availability, and practicality of treatment and its associated side effects, including drug-drug interactions. In this paper, we discuss how we approach managing COVID-19 in patients with hematologic malignancies and recipients of HCT and cell therapy.
UR - http://www.scopus.com/inward/record.url?scp=85135977066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135977066&partnerID=8YFLogxK
U2 - 10.1182/blood.2022016089
DO - 10.1182/blood.2022016089
M3 - Article
C2 - 35776899
AN - SCOPUS:85135977066
SN - 0006-4971
VL - 140
SP - 673
EP - 684
JO - Blood
JF - Blood
IS - 7
ER -